Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases

NCT05236491 is registered in ClinicalTrials.gov with Paul R Fortin as lead sponsor.

NCT NCT05236491
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05236491 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
Lead sponsor
Paul R Fortin
Phase
Phase 2/3
Overall status
Unknown status
Start date
March 9, 2022
Completion date
December 31, 2023
Enrollment
287 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune rheumatologic disease, immunosuppression, overlap connective tissue disease, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, systemic sclerosis, systemic vasculitis, undifferentiated connective tissue diseases